丁丙诺啡镇痛导致健康大鼠凝血病并升高血浆纤维蛋白原:对小动物研究的意义
研究将成年雄性Sprague Dawley大鼠随机分为四组(每组n=6):基线(硫喷妥麻醉)、5%异氟烷麻醉、异氟烷-丁丙诺啡(0.05 mg/kg皮下)和单用丁丙诺啡。给药1小时后麻醉采血,用旋转血栓弹力测定法检测凝血。结果显示异氟烷或丁丙诺啡对EXTEM或INTEM的凝血时间、 clot形成或 clot溶解影响很小或没有影响,但丁丙诺啡显著增加FIBTEM alpha角、 clot形成率和最大 clot形成速度,并增加EXTEM、FIBTEM和INTEM的A10( clot强度)、最大 clot硬度和最大 clot弹性。丁丙诺啡组纤维蛋白原对 clot强度的贡献为基线的1.9倍,异氟烷-丁丙诺啡组为1.4倍;两组的血浆纤维蛋白原水平均为基线或异氟烷组的2.5倍(6.1 g/L vs 2.4 g/L,P < 0.05)。作者结论认为丁丙诺啡镇痛显著增加 clot强度而不影响纤维蛋白溶解,并升高血浆纤维蛋白原,提示该药增加肝脏纤维蛋白原合成和释放。
要点
- 健康大鼠皮下注射丁丙诺啡0.05 mg/kg后,血浆纤维蛋白原为6.1 g/L,基线或异氟烷组为2.4 g/L(P < 0.05),升高2.5倍。
- 丁丙诺啡显著增加FIBTEM alpha角、 clot形成率和最大 clot形成速度,并增加EXTEM、FIBTEM和INTEM的A10、最大 clot硬度和最大 clot弹性。
- 丁丙诺啡组纤维蛋白原对 clot强度的贡献为基线的1.9倍,异氟烷-丁丙诺啡组为1.4倍。
- 异氟烷或丁丙诺啡对EXTEM或INTEM的凝血时间、 clot形成或 clot溶解影响很小或没有影响。
- 作者认为丁丙诺啡增加肝脏纤维蛋白原合成和释放,小动物研究中需考虑该药对凝血指标的影响。
适用人群与场景
- 成年雄性Sprague Dawley大鼠,用于小动物研究中的术后疼痛及相关应激镇痛。
研究设计与关键结果
- 研究类型:动物实验,成年雄性Sprague Dawley大鼠随机分为四组(每组n=6):基线(硫喷妥麻醉)、5%异氟烷麻醉、异氟烷-丁丙诺啡(0.05 mg/kg皮下)、单用丁丙诺啡;给药1小时后麻醉采血,用旋转血栓弹力测定法检测。
- 异氟烷或丁丙诺啡对EXTEM或INTEM的凝血时间、 clot形成或 clot溶解影响很小或没有影响。
- 丁丙诺啡显著增加FIBTEM alpha角、 clot形成率和最大 clot形成速度,并增加EXTEM、FIBTEM和INTEM的A10、最大 clot硬度和最大 clot弹性;异氟烷与丁丙诺啡联用显著增加 clot振幅,但程度不及单用丁丙诺啡。
- 丁丙诺啡组纤维蛋白原对 clot强度的贡献为基线的1.9倍,异氟烷-丁丙诺啡组为1.4倍。
- 丁丙诺啡组和异氟烷-丁丙诺啡组的血浆纤维蛋白原水平均为基线或异氟烷组的2.5倍(6.1 g/L vs 2.4 g/L,P < 0.05)。
证据类型、等级与局限
- 证据类型:动物实验(大鼠)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为丁丙诺啡镇痛显著增加 clot强度而不影响纤维蛋白溶解,并升高血浆纤维蛋白原,提示该药增加肝脏纤维蛋白原合成和释放;小动物研究中需考虑该药对凝血指标的影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Buprenorphine is the recommended analgesic for post-surgical pain and associated stress in small animal research. Our aim was to examine the effect of isoflurane anesthesia and buprenorphine analgesia on blood coagulation in the rat using rotational thromboelastometry.
METHODS: Adult male Sprague Dawley rats were randomly assigned to one of four groups (n = 6): baseline (Thiobarb anesthesia), 5% isoflurane anesthesia, isoflurane-buprenorphine (0.05-mg/kg s.c.), and buprenorphine alone. After 1 h, animals were anesthetized and blood was sampled.
RESULTS: We report that isoflurane or buprenorphine had little or no effects on clotting times, clot formation, or clot lysis in EXTEM or INTEM. However, buprenorphine significantly increased FIBTEM alpha-angle, clot formation rates, and maximum clot formation velocities. Buprenorphine also increased EXTEM, FIBTEM, and INTEM A10 (clot strength), maximum clot firmness (clot quality), and maximum clot elasticity ( (clot elasticity). The combination of isoflurane and buprenorphine significantly increased clot amplitude but not to the same extent. The fibrinogen contribution to clot strength was 1.9-fold higher than baseline in the buprenorphine group, and 1.4-fold higher in the isoflurane-buprenorphine group. Plasma fibrinogen levels were 2.5-fold higher in both groups compared with the baseline value or isoflurane group (6.1 g/L vs. 2.4 g/L, P < 0.05).
CONCLUSIONS: We conclude buprenorphine analgesia significantly increased clot strength without affecting fibrinolysis, and increased plasma fibrinogen, implying that the drug increased liver fibrinogen synthesis and release. Possible implications for small animal research are discussed.
参考来源
- Griffin MJ, Letson HL, Dobson GP, et al. Buprenorphine Analgesia Leads to Coagulopathy and Increased Plasma Fibrinogen in Healthy Rats: Implications For Small Animal Research. Shock. 2017. PMID: 27984521. doi:10.1097/SHK.0000000000000821
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。